Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study
Clinical and Echocardiographic Management of Patients With Chronic Heart Failure and Type 2 Diabetes Mellitus: the SCODIAC Follow up Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Naples, Italy, 80131
- Federico II University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age at least 65 years
- presence of chronic HF, defined as a stable clinical syndrome with typical symptoms and signs and echocardiographic evidence of cardiac involvement
- New York Heart Association (NYHA) class II-III
- diagnosis of T2DM from at least 2 years
Exclusion Criteria:
- cardiac surgery performed during the last year
- age less than 65 years
- significant valvulopathies
- malignant neoplasms
- advanced chronic kidney disease
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
diabetic HF-pEF patients
It is composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (>45%).
|
Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
Other Names:
|
|
diabetic HF-rEF patients
It is composed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%).
|
Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ejection Fraction
Time Frame: 12 months
|
12 months
|
|
|
Total Cholesterol, LDL, HDL Triglycerides, Creatinine
Time Frame: 12 months
|
mg/dl
|
12 months
|
|
B-type natriuretic peptide (BNP)
Time Frame: 12 months
|
pmol/m
|
12 months
|
|
HbA1c
Time Frame: 12 months
|
mmol/L
|
12 months
|
|
Left Ventricular End-Diastolic Volume Index (LV-EDVi), Left Ventricular End-Systolic Volume Index (LV-ESVi), Left Atrial Volume Index (LAVi)
Time Frame: 12 months
|
ml/m2
|
12 months
|
|
E velocity, A velocity,E' velocity
Time Frame: 12 months
|
m/sec
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ugo Oliviero, Federico II University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FedericoIIArcaAmd
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.